Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy

Lancet Oncology

Volumn 8, Issue 8, 2007, Pages 738-743

  Robinson, Alice A ^a   Watson, William J ^b   Leslie, Kimberly K ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; IMATINIB; INFLIXIMAB; LAPATINIB; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; THALIDOMIDE; TRASTUZUMAB; VINCRISTINE;

AUTOIMMUNE DISEASE; BLOOD PLACENTA BARRIER; BREAST CANCER; CANCER; CANCER RESISTANCE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ENDOMETRIUM CANCER; FETOTOXICITY; FETUS MONITORING; GESTATIONAL AGE; HIGH RISK PREGNANCY; HUMAN; HYPERTENSION; LUNG CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS; SOLID TUMOR; TERATOGENICITY; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANT WOMEN; PROTEIN KINASE INHIBITORS;

EID: 34547483563     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70242-5     Document Type: Review

References (49)

1. Joy A., and Mackey J. Adjuvant trastuzumab: progress, controversies, and steps ahead. Curr Oncol 13 (2006) 8-13
2. Slamon D., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
3. Watson W. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 105 (2005) 642-643
4. Waterston A., and Graham J. Effect of adjuvant trastuzumab on pregnancy. J Clin Onc 24 (2006) 321-322
5. Fanale M., Uyei A., Theriault R., et al. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 6 (2005) 354-356
6. Bader A., Schlembach D., Tamussino K., Pristauz G., and Petru E. Anhydramnios associated with the administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 8 (2007) 79-81
7. Lee K., Simon H., Chen H., Bates B., Hung M., and Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378 (1995) 394-398
8. Keefe D. Trastuzumab-associated cardiotoxicity. Cancer 95 (2002) 1592-1600
9. Wilson S., Amsler K., Hyink D., et al. Inhibition of HER-2(neu/ErbB2) restores normal function and structure to polycystic kidney disease (PKD) epithelia. Biochim Biophys Acta 1762 (2006) 647-655
10. Kimby E., Sverrisdottir A., and Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 72 (2004) 292-295
11. Herold M., Schnohr S., and Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 19 (2001) 3439
12. Decker M., Rothermundt C., Hollander G., et al. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 7 (2006) 693-694
13. Ojeda-Uribe M., Gilliot C., Jung G., et al. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinat 26 (2006) 252-255
14. Miller J. Inflammatory bowel disease in pregnancy: a review. J R Soc Med 79 (1986) 221-225
15. Baiocco P., and Korelitz B. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 6 (1984) 211-216
16. Fonager K., Sorensen H., Olsen J., et al. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 93 (1998) 2426-2430
17. Lugering A., Schmidt M., Lugering N., et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 (2001) 1145-1157
18. Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFα monoclonal antibody. Hum Exp Toxicol 19 (2000) 226-228
19. Katz J., Antoni C., Keenan G., et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 99 (2004) 2385-2392
20. Mahadevan U., Kane S., Sandborn W., et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 21 (2005) 733-738
21. Burt M., Frizelle F., and Barbezat G. Pregnancy and exposure to infliximab (anti-tumor necorosis factor-alpha monoclonal antibody). J Gastroenterol Hepatol 18 (2003) 465-466
22. Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn's disease. Am J Gastroenterol 96 (2001) 2274-2275
23. Vesga L., Terdiman J., and Mahadevan U. Adalimumab use in pregnancy. Gut 54 (2005) 890
24. Mishkin D., Van Deinse W., Becker J., and Farraye F. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 12 (2006) 827-828
25. Coburn L., Wise P., and Schwartz D. The successful use of adalimumab to treat active Crohn's disease of an ilieoanal pouch during pregnancy. Dig Dis Sci 51 (2006) 2045-2047
26. Roux C., Brocq O., Breuil V., Albert C., and Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatology 46 (2007) 695-698
27. Kantarjian H., Talpaz M., O'Brien S., et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103 (2004) 2873-2878
28. O'Brien S., Guilhot F., Larson R., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
29. Kantarjian H., O'Brien S., Cortes J., et al. Treatment of Philadelphia chromosome-positive, accelerated phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8 (2002) 2167-2176
30. Heartin E., Walkinshaw S., and Clark R. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma 45 (2004) 1307-1308
31. Ault P., Kantarjian H., O'Brien S., et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24 (2006) 1204-1208
32. Ali R., Ozkalemkas F., Ozcelik T., et al. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 29 (2005) 971-973
33. Hensley M., and Ford J. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 40 (2003) 21-25
34. Alkindi S., Dennison D., and Pathare A. Imatinib in pregnancy. Eur J Haematol 74 (2005) 535-537
35. Choudhary D., Mishra P., Kumar R., et al. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol 17 (2006) 178-179
36. Lary J., Daniel K., Erickson D., Roberts H., and Moore C. The return of thalidomide: can birth defects be prevented?. Drug Saf 21 (1999) 161-169
37. Stephens T., Bunde C., and Fillmore B. Mechanism of action of thalidomide in teratogenesis. Biochem Pharmacol 59 (2000) 1489-1499
38. D'Amato R., Loughnan M., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91 (1994) 4082-4085
39. Rajkumar S., and Witzig T. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26 (2000) 351-362
40. Pietras R., Fendly B., Chazin V., Pegram M., Howell S., and Slamon D. Antibody to Her-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9 (1994) 1829-1838
41. Pietras R., Pegram M., Finn R., Maneval D., and Slamon D. Remission of human breast cancer zenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17 (1998) 2235-2249
42. Coley H., Shotton C., Ajose-Adeogun A., Modjtahedi H., and Thomas H. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitixing EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol 72 (2006) 941-948
43. Longo R., Torino F., and Gasparini G. Targeted therapy of breast cancer. Curr Pharm Des 13 (2007) 497-517
44. Leslie K., Koil C., and Rayburn W. Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin North Am 32 (2005) 627-640
45. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5 (2007) 203-216
46. Reid A., Vidal L., Shaw H., and de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43 (2007) 481-489
47. Stoehlmacher J. Prediction of efficacy and side-effects of chemotherapy in colorectal cancer. Recent Results Cancer Res 176 (2007) 81-88
48. Cohen M., Gootenberg J., Keegan P., and Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12 (2007) 356-361
49. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12 (2006) 642-649